Inhibitors of KRAS G12C mutant proteins

Patent metadata

Field	Value
Publication number	US-9862701-B2
Application number	US-201514866147-A
Country	US
Kind code	B2
Filing date	Sep 25, 2015
Priority date	Sep 25, 2014
Publication date	Jan 9, 2018
Grant date	Jan 9, 2018

Abstract

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I):

or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein R 1 , R 2 , R 3a , R 3b , R 4a , R 4b , G 1 , G 2 , L, m 1 , m 2 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

First claim

The invention claimed is:

1. A compound having the following structure (Ia′):

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
G 1 and G 2 are each N;
L is a bond or alkylene;
X is a bond or CH 2 ;
R 1 is aryl optionally substituted with one or more substituents selected from the group consisting of —OH, halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy and C 1 -C 6 hydroxylalkyl;
R 3a , R 3b , R 4a and R 4b are, at each occurrence, independently H, C 1 -C 6 alkyl or C 2 -C 6 alkynyl
R 5 and R 6 are each independently H, —OH, —CN, halo, C 1 -C 6 alkyl or aminylcarbonyl;
m 1 and m 2 are each 2;
represents a double bond;
Q is —C(═O)—, —C(═NR 7 )—, —NR 8 C(═O)—, —S(═O) 2 —or —NR 8 S(═O) 2 —; and
R 7 , R 8 , R 9 and R 10 are each independently H or C 1 -C 6 alkyl.

2. The compound of claim 1 , wherein the compound has the following structure (Ia″):

3. The compound of claim 1 , wherein R 1 is unsubstituted.

4. The compound of claim 1 , wherein R 1 is substituted with one or more substituents selected from the group consisting of —OH, halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy and C 1 -C 6 hydroxylalkyl.

5. The compound of claim 4 , wherein R 1 is substituted with one or more substituents selected from the group consisting of —OH, halo, C 1 -C 6 alkyl and C 1 -C 6 alkoxy.

6. The compound of claim 1 , wherein R 1 is substituted with C 1 -C 6 haloalkyl.

7. The compound of claim 5 , wherein halo is chloro or fluoro.

8. The compound of claim 1 , wherein R 1 is phenyl or naphthyl, each of which is optionally substituted with one or more substituents selected from the group consisting of —OH, halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy and C 1 -C 6 hydroxylalkyl.

9. The compound of claim 8 , wherein R 1 has one of the following structures:

10. The compound of claim 1 , wherein Q is —C(═O)—.

11. The compound of claim 1 , wherein at least one of R 9 or R 10 is H.

12. The compound of claim 11 , wherein each of R 9 and R 10 are H.

13. The compound of claim 1 , wherein

has one of the following structures:

14. The compound of claim 1 , wherein L is a bond.

15. The compound of claim 1 , wherein each R 3a , R 3b ,R 4a and R 4b is H.

16. The compound of claim 1 , wherein at least one R 3a or at least one R 4a is C 1 -C 6 alkyl.

17. The compound of claim 1 , wherein the compound has one of the following structures:

18. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

Assignees

• Araxes Pharma Llc

Inventors

• Li Liansheng
• Feng Jun
• Ren Pingda
• Liu Yi

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• C07D213/75

  Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates · CPC title

• C07D295/10

  substituted by doubly bound oxygen or sulphur atoms · CPC title

• C07D231/56

  Benzopyrazoles; Hydrogenated benzopyrazoles · CPC title